What's Happening?
Amgen is advancing its weight loss drug candidate, MariTide, which is currently undergoing six phase 3 clinical trials. MariTide is an antibody-peptide conjugate designed to block the receptor for glucose-dependent insulinotropic polypeptide (GIP) and activate
the receptor for glucagon-like peptide-1 (GLP-1). This dual action aims to improve metabolic control, offering a once-monthly injection as opposed to the weekly injections required by competitors Eli Lilly and Novo Nordisk. In a phase 2 trial involving 592 participants, MariTide demonstrated a weight loss of 12.3% to 16.2% over 52 weeks, compared to 2.5% with a placebo. Despite these promising results, MariTide has not yet been tested against leading drugs like Eli Lilly's Zepbound and Novo Nordisk's Wegovy, which have shown higher weight loss percentages in other trials.
Why It's Important?
The development of MariTide represents a potential shift in the weight loss drug market, primarily due to its monthly dosing schedule, which could offer greater convenience for patients. This could lead to increased market share for Amgen if the drug proves effective in phase 3 trials. However, the competition remains fierce, with Eli Lilly and Novo Nordisk already established in the market with proven efficacy. The outcome of Amgen's trials could influence the competitive landscape, potentially affecting the market dynamics and patient preferences in the weight loss drug sector.
What's Next?
Amgen's next significant milestone is the completion of its Maritime-1 trial, a 3,501-patient study, expected to conclude on January 21, 2027. The results of this trial will be crucial in determining MariTide's market viability and its ability to compete with existing treatments. Meanwhile, Eli Lilly and Novo Nordisk continue to develop and potentially release newer therapies, which could further complicate Amgen's entry into the market. The ongoing trials and subsequent results will be closely watched by industry stakeholders and investors.
